



Onxeo announces its financial calendar for 2016

Paris (France), Copenhagen (Denmark), December 15, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces its financial calendar for 2016:

February 26, 2016	Full-year 2015 results
April 6, 2016	General shareholders' meeting (to be convened in Paris)
April 28, 2016	Quarterly information as of March 31, 2016
July 28, 2016	Consolidated accounts for the 1st half of 2016
October 25, 2016	Quarterly information as of September 30, 2016

This financial calendar is for indicative purposes only and Onxeo could change its publication dates should it deem it necessary.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (Doxorubicin Transdrug™)

Validive® (Clonidine Lauriad®)

Beleodaq® (belinostat)

For more information, visit the website www.onxeo.com

To receive our press releases and newsletters, please register on: <http://www.onxeo.com/en/newsletter/>

Follow us on Twitter @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).

Contact:

Nathalie Delair-Trepo
Investor Relations, Onxeo
investors@onxeo.com
+33 1 45 58 76 00

Caroline Carmagnol / Florence Portejoie – Alize RP (France)
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 64

Kirsten Thomas / Lee Roth – The Ruth Group (U.S.)
kthomas@theruthgroup.com / lroth@theruthgroup.com
+1 508 280 6592 / +1 646 536 7012